f*1
2 楼
The drug maker reported positive interim data from a Phase 2 clinical study
evaluating poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer (
NSCLC).
evaluating poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer (
NSCLC).
相关阅读
靠。。幸好昨天put的是微软不是大盘。。江湖总有才人出谁看好BA5 baozis which one will run even wilder? WFR or ERTS这句话是高兴还是不高兴这个video很有意思,休斯敦BMC的Bad Project (转载)Stay away from Mortgage insurers for now大蜜蜂上海的春晚比央视好看多了两房就是妖孽啊,又冲新高到0.85了Who will help to comment on AMD's last ER?draw a line--------------------------etf怎么收management expense?手上有点闲钱,想炒股。谁跟俺说说怎么捐伪币到版上?祝大家兔年平安吉祥,财运亨通, 发88个双黄包JASO突突?大夫, F今天算稳住了吗?第一届“小牛奖”ady